German generics developer Stada Arzneimittel is mulling over a potential $11 billion sale, though there are no concrete and definite plans yet, CEO Peter Goldschmidt confirmed Tuesday.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,